2016 American Transplant Congress » Poster Session B: Drug Minimization

Date: Sunday, June 12, 2016

Time: 6:00pm-7:00pm

Location: Halls C&D

Session Type: Poster Session

Meeting: 2016 American Transplant Congress

6:00pm-7:00pm: A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.

J. Klepacki,¹ J. Klawitter,¹ J. Klawitter,¹ A. Karimpour-fard,² E. Anderson,¹ G. Ingle,³ D. Patel,³ K. Johnson,⁴ D. Cibrik,⁴ U. Christians.¹

6:00pm-7:00pm: A Randomized-Controlled Trial Comparing the Efficacy of CYP3A5 Genotype-Based with Bodyweight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.

N. Shuker,^1,2 R. Bouamar,² R. van Schaik,³ M. Clahsen -van Groningen,⁴ J. Damman,⁵ C. Baan,¹ J. van de Wetering,¹ A. Rowshani,¹ W. Weimar,¹ T. van Gelder,^1,2 D. Hesselink.¹

6:00pm-7:00pm: A Weighted Approach to Composite Efficacy Analysis in Kidney Transplantation.

B. Kaplan, K. MaCague, D. Patel, F. Vincenti.

6:00pm-7:00pm: Advantages of Computerized Dosing Strategy in Tacrolimus Treatment of Renal Transplant Patients.

S.-Y. Kim,¹ S. Cho,¹ M.-J. Cho,¹ C. Lee,¹ A. Han,¹ C. Choi,¹ S. Ahn,¹ S.-I. Min,¹ S.-K. Min,¹ M. Park,² I. Jung,³ S. Kim,⁴ J. Ha.^1,2

6:00pm-7:00pm: Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.

Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ T. Nagai,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²

6:00pm-7:00pm: Clinical Factors That Determine the Appropriateness of Early Steroid Withdrawal.

S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, D. Segev.

6:00pm-7:00pm: Clinical Outcomes of Simplified Once-Daily Immunosuppressive Regimen for Kidney Recipients.

C.-K. Oh,¹ S.-J. Kim,² K. Huh,³ S. Kim,⁴ H. Cho,⁵ S. Lee.⁶

6:00pm-7:00pm: Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.

Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ T. Nagai,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²

6:00pm-7:00pm: Comparison of Transplant Outcomes for Low-Dose and Standard-Dose Tacrolimus in Kidney Transplant Recipients.

J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, E. Kwon, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim, C.-D. Kim.

6:00pm-7:00pm: Do We Need an Individually Tailored Immunosuppression Strategy for Living Donor Kidney Transplant Recipients with PreTransplant Donor Specific Antibodies? A Retrospective Analysis.

S. Bhutani,¹ A. Ponnusamy,² Q. Tak,¹ S. Shah,¹ J. Worthington,¹ A. Summers,¹ K. Poulton,¹ D. Van Dellen,¹ M. Morton,¹ M. Picton.¹

6:00pm-7:00pm: Elderly Kidney Transplant Recipients Need Optimized Immunosuppression According to Comorbidity and Infection.

E. Kang,¹ S. Park,¹ S. Park,¹ S. Yang,² I. Jung,³ S.-K. Park,⁴ Y. Kim,⁵ D.-J. Han,¹ Y. Kim,¹ J. Lee.⁶

6:00pm-7:00pm: Evaluation According to Donor Source: 24-Month Results from Post-Hoc Analysis of the ELEVATE Study in Kidney Transplant Recipients.

J. de Fijter, H. Holdaas, P. Lopez, P. Bernhardt, D. Gaohong, J. Cruzado, M. van der Giet.

6:00pm-7:00pm: Evaluation of an Early Steroid Withdrawal Maintenance Regimen in African American Renal Transplant Recipients.

S. Gabardi, M. Kim, R. Alsheikh, K. Townsend, A. Chandraker.

6:00pm-7:00pm: Everolimus and Low Dose Cyclosporine Immunosuppressive Regimen and Development of Anti HLA Donor Specific Antibodies.

E. Minetti,¹ L. Di Maria,¹ L. Caroti,¹ E. Buti,² P. Carta.¹

6:00pm-7:00pm: High Tacrolimus Dose Requirements at Month 6 Are Associated with Inferior Graft Function in Renal Transplant Patients.

O. Rissling, S. Brakemeier, L. Lehner, F. Halleck, O. Staeck, D. Schmidt, K. Budde.

6:00pm-7:00pm: How Tacrolimus Variability Affects Donor Specific Antibodies, Rejection and Outcome After Kidney Transplantation.

S. Papachristos, A. John Velvet, A. Summers, A. Tavakoli, R. Dhanda, R. Pararajasingam, B. Forgacs.

6:00pm-7:00pm: Impact of Ethnicity on Tacrolimus Trough/Dose Ratios Following Solid Organ Transplantation.

A. Santeusanio, A. Owusu-Obeng, J. Jeff.

6:00pm-7:00pm: Impact of HLA-DR Compatibility on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.

J. Cruzado, H. Holdaas, P. Lopez, J. Aguilar, G. Dong, F. Claas, W. Arns, M. van der Giet, J. de Fijter.

6:00pm-7:00pm: Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study.

B. Nashan,¹ M. van der Giet,¹ H. Holdaas,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ J. Cruzado,¹ J. De Fijter.¹

6:00pm-7:00pm: Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 7 Years Follow-Up.

Y. Watarai, M. Okada, K. Futamura, T. Nagai, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi.

6:00pm-7:00pm: Outcomes of Hispanic Kidney Transplant Recipients Under a Cyclosporine versus Tacrolimus Based Immunosuppression Protocol.

P. West-Thielke, A. Lasky, J. Thielke, M. Campara, E. Benedetti.

6:00pm-7:00pm: Pediatric Patients Benifit from Steroids Free Regimen After Kidney Transplantation: A Meta-Analysis.

R. Deng, H. Zhang, Y. Zheng, L. Liu, C. Wang.

6:00pm-7:00pm: Prospective Randomized Study of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant.

A. Shetty, O. Traitanon, M. Ansari, J. Mathew, J. Leventhal, V. Mas, L. Gallon.

6:00pm-7:00pm: Quadruple Induction Regimen with Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Improves Graft Function without Increase in the Incidence of Microvascular Inflammation or De Novo Donor Specific Antibody Compared to the Standard Triple Regimen.

M. Miura, H. Higashiyama.

6:00pm-7:00pm: Rapid Discontinuation of Prednisone (RDP) in Kidney Transplant (KTx) Recipients: 15-Year Outcomes.

O. Serrano,¹ R. Kandaswamy,¹ K. Gillingham,¹ W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ H. Ibrahim,² A. Kukla,² R. Spong,² N. Issa,² T. Pruett,¹ A. Matas.¹

6:00pm-7:00pm: Renal Dysfunction at 12 Months Is Not Associated with Everolimus Exposure in De Novo Renal Transplant Recipients.

F. Shihab,¹ Y. Qazi,² S. Mulgaonkar,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ D. Shaffer.⁶

6:00pm-7:00pm: Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients.

B. Chopra, K. Sureshkumar.

6:00pm-7:00pm: Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.

H.-P. Chang,¹ C.-Y. Lee,² C.-C. Si,¹ M.-K. Tsai,² F.-L. Lin Wu.^1,3

6:00pm-7:00pm: Steroid Free Immunosuppression and Clinical Outcomes in Recipients of Deceased Donor Kidney Transplant with Positive Flow Cytometry Crossmatch.

O. Adebiyi, T. Taber, W. Goggins, D. Mishler, M. Yaqub, A. Sharfuddin.

6:00pm-7:00pm: Stratification of Kidney Transplant Recipients into Those with Low and High Alloreactive T-Cells May Allow Safe Conversion to mTOR-Inhibitor-Based Immunosuppression.

T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2

6:00pm-7:00pm: TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients[mdash]Baseline Characteristics.

M. Henry.

6:00pm-7:00pm: The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.

E. Woodle,¹ D. Kaufman,² A. Shields,¹ J. Leone,³ A. Matas,⁴ A. Wiseman,⁵ P. Thielke,⁶ R. Alloway.¹

« View all sessions from the 2016 American Transplant Congress